Table 4.
Treatment arms: | TAF/FTC/EVG/c | TDF/FTC/EVG/c |
---|---|---|
(n=866) | (n=867) | |
HIV RNA <50 copies/mL | 87% | 85% |
Virological failure | 5% | 5% |
Drug resistance | 1.2% | 0.9% |
Grade 3 or 4 clinical adverse events | 12% | 12% |
Grade 3 or 4 laboratory adverse events | 28% | 25% |
c: cobicistat; EVG: elvitegravir; FTC: emtricitabine; TAF: tenofovir alafenamide; TDF: tenofovir disoproxil fumarate.